Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Source:
    Stroke; a journal of cerebral circulation 2020 51 1, 224 (224-231)
  • Additional Information
    • Author(s):
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Meng X, Li H, Wang Y, CHANCE Investigators
    • Language:
      English
    • Publication Type:
      Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    • Record Status:
      This record is this issue.
    • Abstract:
      Background and Purpose- The role of dual-antiplatelet therapy with clopidogrel plus aspirin has been demonstrated to substantially decrease the risk of recurrent stroke among patients with minor stroke and transient ischemic attack. We aimed to determine whether the efficacy of clopidogrel-aspirin therapy among patients with minor stroke / transient ischemic attack was influenced by the stratification of CYP2C19 genotype and body mass index (BMI). Methods- CYP2C19 loss-of-function allele (LoFA) carriers were defined as patients with either LoFA of *2 or *3. Low/normal weight and overweight/obesity was defined as BMI
    • Medical Subject Headings (MeSH):
      Aged
      Female
      Humans
      Male
      Middle Aged
      Alleles
      Body Mass Index
      Double-Blind Method
      Loss of Function Mutation
      Obesity/drug therapy
      Obesity/enzymology
      Obesity/genetics
      Risk Factors
      Stroke/drug therapy
      Stroke/enzymology
      Stroke/genetics
      Aspirin/*administration & dosage
      Clopidogrel/*administration & dosage
      Cytochrome P-450 CYP2C19/*genetics
    • Source:
      This document should be cited as: Mo J Chen Z Xu J Wang A Dai L Cheng A Meng X Li H Wang Y CHANCE Investigators. Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity 2020 (The Cochrane Controlled Trials Register (CCTR/CENTRAL). DOI: 10.1161/STROKEAHA.119.026845. Oxford: Update Software. Updated quarterly.
    • Accession Number:
      CN-02090051
  • Citations
    • ABNT:
      MO J et al. Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke; a journal of cerebral circulation, [s. l.], v. 51, n. 1, p. 224–231, 2020. DOI 10.1161/STROKEAHA.119.026845. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cgh&AN=CN-02090051. Acesso em: 29 set. 2020.
    • AMA:
      Mo J, Chen Z, Xu J, et al. Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke; a journal of cerebral circulation. 2020;51(1):224-231. doi:10.1161/STROKEAHA.119.026845
    • APA:
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Meng X, Li H, Wang Y, & CHANCE Investigators. (2020). Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke; a Journal of Cerebral Circulation, 51(1), 224–231. https://doi.org/10.1161/STROKEAHA.119.026845
    • Chicago/Turabian: Author-Date:
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Meng X, Li H, Wang Y, and CHANCE Investigators. 2020. “Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.” Stroke; a Journal of Cerebral Circulation 51 (1): 224–31. doi:10.1161/STROKEAHA.119.026845.
    • Harvard:
      Mo J et al. (2020) ‘Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity’, Stroke; a journal of cerebral circulation, 51(1), pp. 224–231. doi: 10.1161/STROKEAHA.119.026845.
    • Harvard: Australian:
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Meng X, Li H, Wang Y & CHANCE Investigators 2020, ‘Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity’, Stroke; a journal of cerebral circulation, vol. 51, no. 1, pp. 224–231, viewed 29 September 2020, .
    • MLA:
      Mo J, et al. “Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.” Stroke; a Journal of Cerebral Circulation, vol. 51, no. 1, Jan. 2020, pp. 224–231. EBSCOhost, doi:10.1161/STROKEAHA.119.026845.
    • Chicago/Turabian: Humanities:
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Meng X, Li H, Wang Y, and CHANCE Investigators. “Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.” Stroke; a Journal of Cerebral Circulation 51, no. 1 (January 1, 2020): 224–31. doi:10.1161/STROKEAHA.119.026845.
    • Vancouver/ICMJE:
      Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, et al. Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke; a journal of cerebral circulation [Internet]. 2020 Jan 1 [cited 2020 Sep 29];51(1):224–31. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cgh&AN=CN-02090051